KR20240099193A9 - Erbb 억제제로서의 다형체 - Google Patents
Erbb 억제제로서의 다형체Info
- Publication number
- KR20240099193A9 KR20240099193A9 KR1020247013097A KR20247013097A KR20240099193A9 KR 20240099193 A9 KR20240099193 A9 KR 20240099193A9 KR 1020247013097 A KR1020247013097 A KR 1020247013097A KR 20247013097 A KR20247013097 A KR 20247013097A KR 20240099193 A9 KR20240099193 A9 KR 20240099193A9
- Authority
- KR
- South Korea
- Prior art keywords
- polymorphs
- erbb inhibitors
- erbb
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163246451P | 2021-09-21 | 2021-09-21 | |
| US63/246,451 | 2021-09-21 | ||
| PCT/US2022/044232 WO2023049168A1 (en) | 2021-09-21 | 2022-09-21 | Polymorphs as erbb inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20240099193A KR20240099193A (ko) | 2024-06-28 |
| KR20240099193A9 true KR20240099193A9 (ko) | 2025-12-10 |
Family
ID=83691602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247013097A Pending KR20240099193A9 (ko) | 2021-09-21 | 2022-09-21 | Erbb 억제제로서의 다형체 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240425492A1 (https=) |
| EP (1) | EP4405350A1 (https=) |
| JP (1) | JP2024534517A (https=) |
| KR (1) | KR20240099193A9 (https=) |
| CN (1) | CN119110799A (https=) |
| AU (1) | AU2022352658A1 (https=) |
| CA (1) | CA3231697A1 (https=) |
| IL (1) | IL311354A (https=) |
| MX (1) | MX2024003475A (https=) |
| WO (1) | WO2023049168A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| CN120769850A (zh) * | 2023-03-02 | 2025-10-10 | 江苏康缘药业股份有限公司 | 一种炔基取代的喹唑啉化合物的晶型、其制备方法和应用 |
| WO2025038731A1 (en) * | 2023-08-15 | 2025-02-20 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
| WO2025137424A1 (en) * | 2023-12-21 | 2025-06-26 | Black Diamond Therapeutics, Inc. | Solid forms of an erbb inhibitor |
| WO2025137421A1 (en) * | 2023-12-21 | 2025-06-26 | Black Diamond Therapeutics, Inc. | Compositions comprising alkyne substituted quinazoline derivatives and related uses |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020328598A1 (en) * | 2019-08-15 | 2022-03-03 | Black Diamond Therapeutics, Inc. | Alkynyl quinazoline compounds |
| US20240075042A1 (en) * | 2020-11-02 | 2024-03-07 | Black Diamond Therapeutics, Inc. | Method of treating cancers with alkyne substituted quinazoline derivatives |
-
2022
- 2022-09-21 CA CA3231697A patent/CA3231697A1/en active Pending
- 2022-09-21 MX MX2024003475A patent/MX2024003475A/es unknown
- 2022-09-21 AU AU2022352658A patent/AU2022352658A1/en active Pending
- 2022-09-21 CN CN202280075401.6A patent/CN119110799A/zh active Pending
- 2022-09-21 WO PCT/US2022/044232 patent/WO2023049168A1/en not_active Ceased
- 2022-09-21 EP EP22789775.8A patent/EP4405350A1/en active Pending
- 2022-09-21 JP JP2024517482A patent/JP2024534517A/ja active Pending
- 2022-09-21 IL IL311354A patent/IL311354A/en unknown
- 2022-09-21 KR KR1020247013097A patent/KR20240099193A9/ko active Pending
- 2022-09-21 US US18/693,733 patent/US20240425492A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022352658A1 (en) | 2024-03-21 |
| EP4405350A1 (en) | 2024-07-31 |
| IL311354A (en) | 2024-05-01 |
| US20240425492A1 (en) | 2024-12-26 |
| JP2024534517A (ja) | 2024-09-20 |
| KR20240099193A (ko) | 2024-06-28 |
| CA3231697A1 (en) | 2023-03-30 |
| MX2024003475A (es) | 2024-04-05 |
| CN119110799A (zh) | 2024-12-10 |
| WO2023049168A1 (en) | 2023-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20240099193A9 (ko) | Erbb 억제제로서의 다형체 | |
| EP4262803A4 (en) | Tetrahydropyridopyrimidine pan-kras inhibitors | |
| EP4110333A4 (en) | Sos1 inhibitors | |
| DK4165024T3 (da) | Cyclobutyldihydroquinolinsulfonamid-forbindelser | |
| EP4216951A4 (en) | KRAS G12D INHIBITORS | |
| IL292754A (en) | Method of synthesis | |
| EP4076418A4 (en) | Sos1 inhibitors | |
| EP4197538A4 (en) | Egfr inhibitor | |
| IL311616A (en) | Egfr inhibitor polymorph forms | |
| PL4192839T3 (pl) | Związki pośrednie remdesiwiru | |
| EP4434979A4 (en) | KIF18A INHIBITOR | |
| IL310528A (en) | Pyrazolopyridinone compounds | |
| EP4358963A4 (en) | SOS1 INHIBITORS | |
| EP4149556C0 (en) | PEG LIPIDOIDS COMPOUNDS | |
| EP4293025C0 (en) | COMPOSED WITH 4-AMINOQUINAZOLINE | |
| DK4320112T3 (da) | Pyridinylsubstituerede oxoisoindolinforbindelser | |
| EP4143199C0 (en) | NUCLEOTIDE PROMEDICINAL COMPOUNDS | |
| EP4168398A4 (en) | TYK-2 INHIBITOR | |
| EP4206080A4 (en) | DEGAZER | |
| EP4247372A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4210694A4 (en) | PLASMA KALLICREIN INHIBITORS | |
| EP4206182A4 (en) | ESTER COMPOUND | |
| EP4433585A4 (en) | NEW OMNI CRISPR NUCLEASE | |
| EP4405334C0 (en) | Sortilin inhibitors | |
| EP4359402C0 (en) | IMIDAZOLO-INDAZOLE COMPOUNDS USED AS JAK INHIBITORS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P19 | Errors in documents containing ipogçös decisions corrected |
Free format text: ST27 STATUS EVENT CODE: A-3-3-P10-P19-OTH-PG1701 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PG1701 | Publication of correction |
St.27 status event code: A-3-3-P10-P19-oth-PG1701 Patent document republication publication date: 20251210 Republication note text: Request for Correction Notice (Document Request) Gazette number: 1020240099193 Gazette reference publication date: 20240628 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |